Cytokinetics (CYTK) AI Stock Analysis

• Market Cap: $4.45B
• Dividend Yield: N/A
• Average Volume (3M): 1.42M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.01
• Revenue Growth: 412.21%
• EPS Growth: 1.75%
• Country: US
• Employees: 498
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): -1.36
• Shares Outstanding: 119,427,290
• 10 Day Avg. Volume: 1,549,101
• 30 Day Avg. Volume: 1,424,233
• PEG Ratio: 12.72
• Price to Book (P/B): -16.76
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -10.99
• Enterprise Value/Market Cap: 1.18
• Enterprise Value/Revenue: 119.35
• Enterprise Value/Gross Profit: -20.12
• Enterprise Value/Ebitda: -2.69
• 1Y Price Target: $74.77
• Price Target Upside: 98.33% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 16

• Rating: 47 Neutral
• Price Target: $34.00 ▼(-9.81%Downside)

Cytokinetics faces severe financial difficulties, significantly impacting its stock score. The balanced sentiment from the earnings call and some technical strength provide moderate support, but valuation metrics and financial performance weigh heavily on the overall score.

Positive Factors

Clinical Trial Success

CYTK's lead asset aficamten demonstrated superiority to beta blocker metoprolol in the pivotal Ph.3 MAPLE-HCM trial, meeting its primary endpoint of improved peak oxygen uptake in patients with obstructive hypertrophic cardiomyopathy.

Product Differentiation

Aficamten is believed to provide a differentiated profile relative to Camzyos, with advantages in efficacy, safety, and pharmacology.

Regulatory Review

With aficamten under regulatory review in the US, EU, and China, these comparative efficacy data could help it strengthen its commercial positioning.

Negative Factors

Adverse Events

Concerns exist regarding a potential increase in adverse events and missed LVEF drops due to the Camzyos label change.

Insurance Coverage

With KOLs already struggling to envision scenarios in which payers will broadly cover afi in the 1L setting, the lack of any insight complicates evaluating the opportunity.

Market Uncertainty

The lack of commentary over the secondary endpoints isn't likely to assuage investor concerns about the 1L.

Cytokinetics Business Overview & Revenue Model

Company Description

Cytokinetics, Inc. is a late-stage biopharmaceutical company focused on the discovery and development of muscle biology-driven therapies. The company is primarily engaged in developing small molecule therapeutics to address diseases characterized by muscle dysfunction and weakness. Cytokinetics' core products include drug candidates aimed at treating conditions such as amyotrophic lateral sclerosis (ALS), heart failure, and hypertrophic cardiomyopathy (HCM). By leveraging its expertise in muscle biology and pharmacology, the company aims to transform the treatment landscapes of severe and debilitating diseases.

How the Company Makes Money

Cytokinetics generates revenue primarily through strategic partnerships, research and development collaborations, and milestone payments from pharmaceutical companies. These partnerships often involve the licensing of its drug candidates or proprietary technology, which in turn provides upfront payments, milestone payments upon achieving clinical or regulatory goals, and potential royalties on future sales. Additionally, the company may receive funding from grants and other non-dilutive sources to support its research and development efforts. Cytokinetics' business model is heavily reliant on the successful development and commercialization of its drug candidates, alongside securing and maintaining partnerships with larger pharmaceutical firms.

Cytokinetics Financial Statement Overview

Summary

Cytokinetics is experiencing significant financial challenges. The income statement indicates negative profitability and declining revenue. The balance sheet shows high leverage with negative equity, posing solvency risks. Negative cash flows further reflect operational inefficiencies and reliance on external financing.

Income Statement

The company is experiencing negative profitability with a declining trend in key metrics. The gross profit margin is significantly negative, indicating cost issues relative to revenue. Net income is deeply negative, and the net profit margin has deteriorated. Revenue growth showed inconsistency with a significant drop recently, impacting the company's ability to cover expenses.

Balance Sheet

The balance sheet reveals high leverage with a negative stockholders' equity, indicating financial instability. The debt-to-equity ratio is unmanageable due to negative equity, posing a risk of solvency issues. Total assets have not seen significant growth, and the equity ratio is negative, indicating more liabilities than assets.

Cash Flow

Cash flow metrics indicate operational struggles with consistent negative operating and free cash flow. The operating cash flow to net income ratio is concerning due to substantial negative income. Despite positive financing cash flows, free cash flow remains negative, reflecting challenges in generating cash from core operations.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	18.47M	7.53M	94.59M	70.43M	55.83M
Gross Profit	8.94M	-322.59M	-146.22M	-89.51M	-41.12M
EBITDA	-493.48M	-456.68M	-329.40M	-176.34M	-86.78M
Net Income	-589.53M	-526.24M	-402.55M	-242.37M	-164.13M
Balance Sheet
Total Assets	1.40B	824.32M	1.01B	841.32M	533.80M
Cash, Cash Equivalents and Short-Term Investments	1.08B	614.82M	782.58M	471.64M	464.06M
Total Debt	788.68M	755.77M	749.34M	269.93M	138.94M
Total Liabilities	1.54B	1.21B	1.12B	597.46M	420.42M
Stockholders Equity	-135.37M	-386.32M	-107.90M	243.86M	113.38M
Cash Flow
Free Cash Flow	-399.80M	-415.75M	-310.85M	-191.39M	-2.11M
Operating Cash Flow	-395.89M	-414.33M	-299.52M	-142.52M	8.94M
Investing Cash Flow	-553.10M	239.25M	-262.13M	-147.78M	-196.51M
Financing Cash Flow	930.61M	221.32M	516.17M	319.98M	234.12M

Cytokinetics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 37.70
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CYTK, the sentiment is Positive. The current price of 37.7 is above the 20-day moving average (MA) of 35.66, above the 50-day MA of 33.40, and below the 200-day MA of 43.66, indicating a neutral trend. The MACD of 1.22 indicates Negative momentum. The RSI at 60.42 is Neutral, neither overbought nor oversold. The STOCH value of 55.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CYTK.

Cytokinetics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VRNA	68 Neutral	$8.93B	―	-72.73%	―	―	-157.53%
IONS	58 Neutral	$6.65B	―	-118.53%	―	-7.65%	-11.81%
AXSM	54 Neutral	$5.50B	―	-282.16%	―	72.16%	9.65%
ZLAB	52 Neutral	$3.84B	―	-32.01%	―	43.59%	28.72%
Sector *	52 Neutral	$7.46B	-0.04	-63.82%	2.49%	16.43%	<0.01%
PCVX	50 Neutral	$4.61B	―	-19.66%	―	―	7.75%
CYTK	47 Neutral	$4.45B	―	435.49%	―	412.21%	1.75%

Cytokinetics Corporate Events

Cytokinetics Announces Key Decisions at Annual Meeting

At its Annual Meeting of Stockholders on May 14, 2025, Cytokinetics announced several key decisions. Stockholders elected three Class III Directors, approved amendments to increase shares under the 2004 Equity Incentive Plan and the Certificate of Incorporation, ratified Ernst & Young LLP as the independent accounting firm for 2025, and endorsed executive compensation. These decisions reflect strategic adjustments in governance and financial structuring, potentially impacting the company’s operational capacity and shareholder value.

The most recent analyst rating on (CYTK) stock is a Buy with a $55.00 price target. To see the full list of analyst forecasts on Cytokinetics stock, see the CYTK Stock Forecast page.